Related Experiment Videos
Malignant CD5 B cells--biased immunoglobulin variable gene usage and autoantibody production
1Department of Surgery, Mount Sinai School of Medicine, New York, New York 10029.
International Reviews of Immunology
|January 1, 1991
Summary
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) malignant CD5 B cells show biased immunoglobulin gene usage and produce autoantibodies. CD5 gene transcription is identical across T cell malignancies and CLL/SLL.
Area of Science:
- Immunology
- Hematology
- Molecular Biology
Background:
- Malignant CD5 B cells characterize chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Understanding their molecular features, including immunoglobulin gene usage and autoantibody production, is crucial for disease characterization.
Purpose of the Study:
- To analyze immunoglobulin variable gene usage, CD5 gene expression, and autoantibody production in malignant CD5 B cells from CLL and SLL patients.
- To investigate the transcription of the CD5 gene in various lymphoid malignancies.
Main Methods:
- Analysis of immunoglobulin variable gene families (VH5, VH6, VKIII) in malignant CD5 B cells.
- Assessment of CD5 gene transcription in T cell malignancies, CLL, SLL, and EBV-transformed cell lines.
- Production and characterization of autoantibodies from heterohybridomas derived from CLL cells and a mouse myeloma line.
Main Results:
- A statistically significant biased usage of VH5, VH6, and VKIII immunoglobulin variable gene families was observed.
- Identical CD5 gene transcription was found in T cell malignancies, CLL, SLL, and EBV-transformed lines.
- A substantial fraction of heterohybridomas secreted monospecific, bispecific, and polyspecific autoantibodies.
Conclusions:
- Malignant CD5 B cells in CLL and SLL exhibit specific patterns of immunoglobulin gene utilization.
- The CD5 gene exhibits conserved transcriptional patterns across related lymphoid malignancies.
- CLL-derived heterohybridomas are a valuable source for studying autoantibody production, highlighting the potential for diverse autoantibody specificities.